SIGNIFICANT AGREEMENTS AND CONTRACTS (Tables)

3 Months Ended

Mar. 31, 2022

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Summary of Collaborative Agreement Liabilities and Revenues Disaggregated by Timing of Revenue Recognition

The following table presents a summary of the activity in the Company's contract liabilities (recorded as deferred revenue on the balance sheet) pertaining to the Mundipharma Collaboration Agreement and Janssen Collaboration Agreement during the three months ended March 31, 2022 (in thousands):


Opening balance, December 31, 2021	$	32,333
Payments received in advance	—
Payments receivable	1,508
Revenue from performance obligations satisfied during reporting period	(2,352)
Closing balance, March 31, 2022	$	31,489

Current portion of deferred revenue	$	14,260
Long-term portion of deferred revenue	17,229
Total deferred revenue, March 31, 2022	$	31,489

The following table presents our contract revenues disaggregated by timing of revenue recognition and excludes royalty revenue (in thousands):


	Three Months Ended March 31, 2022
	Point in Time		Over Time
Revenue from Mundipharma Collaboration Agreement:

Research and Development Services	$	—	$	2,274
Clinical Supply Services	—		252
Total revenue from Mundipharma Collaboration Agreement	$	—	$	2,526

Revenue from Janssen Collaboration Agreement:
License of Intellectual Property	$	816	$	—
Research and Development Services	—		2,356
Clinical Supply Services	—		1,411
Total revenue from Janssen Collaboration Agreement	$	816	$	3,767


	Three Months Ended March 31, 2021
	Point in Time		Over Time
Revenue from Mundipharma Collaboration Agreement:

Research and Development Services	$	—	$	2,331
Clinical Supply Services	—		77
Total revenue from Mundipharma Collaboration Agreement	$	—	$	2,408